DALLAS, May 24 /PRNewswire/ -- An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.
The first product, IV-7 Ultimate Germ Defense™, is a revolutionary, patented, broad-spectrum germ-killing treatment for hard surfaces. It kills viruses, bacteria and fungi in as quickly as 30 seconds, using the first new disinfectant technology approved by the EPA in 30 years.
IV-7 has no odor or fumes, does not cause skin irritation, and creates an invisible barrier of protection that continues killing germs for 24 hours.
It will be brought to the consumer market through a new direct selling company called IV-7 Direct, using a multi-level sales model. Independent sales representatives will earn commissions selling the product and also from the sales of people who they enlist into the business.
John Rochon, former chairman of Mary Kay Inc. and a veteran of over 20 years in the direct selling industry, is heading IV-7 Direct, which is part of Dallas-based Richmont Holdings. A related company, Richmont Sciences, is the sales and marketing arm of IV-7's manufacturer, Pure Biosciences of San Diego ( PURE).
"We have an obligation to get this product into the war on germs as quickly as possible, to protect our loved ones and save lives," said Mr. Rochon.
"IV-7 is too special to put on store shelves. Through the person-to-person contact of direct selling, we can show consumers how these products are different and spread the word quickly."
"When I decided to return to the direct selling industry, I wanted to approach it in a new way. I wanted a new business model that did two things: First, get this product into the hands of millions of people quickly without a multi-million dollar advertising campaign; Second, give sellers a unique binary and unilevel compensation plan that can replenish the savings they've lost in the recession."
IV-7's patented formula is powered by silver dihydrogen citrate (SDC), which has been proven effective against viruses, bacteria and fungi including H1N1, MRSA, Salmonella, E. coli, Norovirus, Influenza A, VRE, Campylobachter jejuni, Staphylococcus aureus and other pathogens.
PURE is developing additional uses for SDC in areas such as personal care products, pharmaceuticals and food processing. Additional products will be added to the IV-7 Direct lineup.
|SOURCE IV-7 Direct|
Copyright©2010 PR Newswire.
All rights reserved